Latest news with #IBSA
Yahoo
2 days ago
- Business
- Yahoo
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio
Business Wire
27-05-2025
- Health
- Business Wire
Two Young Researchers from US Institutions among the Six Winners of the 12
PARSIPPANY, N.J.--(BUSINESS WIRE)--Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships program, which for over a decade, has supported talented young researchers from universities and research institutions around the world. The program awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; and has been a constantly growing success, as demonstrated by the 259 applications received for the 2024 edition, which marked a new record, across five therapeutic areas. This year, the scientific board of IBSA Foundation selected, among others, two young researchers from Californian research institutes: Vanessa Lopez Polo, Ph.D. (University of California, San Francisco), 32, and of Spanish origins, and Enchen Zhou, Ph.D. (University of California San Diego), 34, of Chinese heritage. Vanessa Lopez Polo, a researcher at the Cardiovascular Research Institute UCSF, received the award in the Healthy Aging/Regenerative Medicine category for her project ' Exploring the role of macrophage-mediated heterophagy in aging and its potential for enhancing tissue health,' which investigates heterophagy, a key cellular quality control mechanism essential for tissue homeostasis. The project aims to understand how aging affects this process and how new therapies might be developed to promote healthy aging by modulating the immune system. Enchen Zhou, who is based at the Glass Laboratory – UC San Diego, was awarded in the Endocrinology category for his project ' Targeting Intestinal-Specific Transcription Factors to Enhance GLP-1 Release: A Novel Approach for Treating Obesity, Diabetes, and MASLD.' This study focuses on improving the regulation of glucagon-like peptide 1 (GLP-1), a key therapeutic target for cardiometabolic diseases such as obesity and diabetes. 'More than ever, it is critically important that we support young and talented researchers in their scientific endeavors. Here at IBSA, we are proud that our Foundation awards these fellowships so that these researchers can conduct cutting-edge science that can work towards improving patients' lives, ' stated Carolyn Kong, PharmD, Chief Business and Medical Affairs Officer, IBSA USA. Since its launch in 2012, the IBSA Foundation Fellowship program has attracted increasing interest, with 1,645 project submissions from researchers under the age of 40 and from 60 countries. Over twelve editions, 58 projects have been funded, totaling €1.6 million. Each fellowship, now worth €32,000, is awarded to research projects in five traditionally underexplored scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/rheumatology/orthopedics and healthy aging/regenerative medicine. A particularly noteworthy statistic is the high number of submissions from female researchers: 1,041 out of 1,645 applications, or around 63%, which testifies to their increasingly central role in international scientific research. ' Supporting the talent of young researchers represents for IBSA Foundation a strategic investment, driving scientific progress and fostering a society that is more aware and better equipped to face future challenges. In a context where access to a scientific career is increasingly complex, our Fellowships serve as a tangible tool to recognize merit and promote innovation, ' stated Silvia Misiti, Director of IBSA Foundation for scientific research. At the Milan (Italy) event, IBSA Foundation announced the opening of the call for proposals for the 2025 Fellowships. As previously held in 2024, the new edition will award six €32,000 grants in the same five scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/rheumatology/orthopedics and healthy aging/regenerative medicine. The sixth scholarship will be assigned to the category that receives the highest number of applications. Beginning this year, the IBSA Foundation Research Equity Prize will also be introduced: worth €5,000, the prize will be awarded to the best scientific project developed in a laboratory, research institute, or university based in a developing country. Researchers wishing to apply must submit their proposals by January 31, 2026, through the platform. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Foundation for scientific research Established in 2012 in Lugano by the pharmaceutical company IBSA (Institut Biochimique SA), IBSA Foundation for scientific research is the main promoter of IBSA Group's social responsibility activities. The Foundation promotes 'Science for all' through accessible information and activities that unite scientific and humanistic culture. Its initiatives include high-level forums featuring internationally renowned scientists, educational events, conferences on art-and-science and health-and-culture and research scholarships in various areas of basic and clinical research. Expand PM-1113-v2 (v2.0)
Associated Press
07-04-2025
- Business
- Associated Press
IBSA celebrates 40 years of Leadership and Innovation
IBSA (Institut Biochimique SA), marks a significant milestone this year as it celebrates 40 years under the leadership of President and CEO Arturo Licenziati. 'Small companies only grow if they adapt quickly to sectors large pharma companies often overlook. We have always been a forward-looking company, ready to go beyond and explore new, unchartered paths.' — Arturo Licenziati GROOMBRIDGE, EAST SUSSEX, UNITED KINGDOM, April 7, 2025 / / -- IBSA celebrates 40 years of history 'Drugs in the best form' – a success story that combines innovation with a focus on people In 1985, IBSA (Institut Biochimique SA) was a small company in Lugano on the brink of bankruptcy. Today, 40 years later, the company celebrates the anniversary of its acquisition by its current CEO and President, Arturo Licenziati, who has led the business with a key philosophy: 'Drugs in the best form'. Lugano, April 3, 2025 – The year 2025 marks an important year for the IBSA Group (Institut Biochimique SA), which celebrates a double anniversary: 40 years of leadership by its CEO and President Arturo Licenziati, and 80 years since the creation of the IBSA name. These milestones coincide with another significant event: the 90th birthday of President Licenziati, who today – April 3, 2025 – celebrates this major occasion. To mark the company's 40th anniversary, IBSA has decided to grant all employees worldwide a day off on August 19, the date when Arturo Licenziati first stepped into IBSA. 'This is just a symbolic gesture to express my gratitude for the commitment, dedication and passion of our People, who are the driving force behind our growth. A growth that is not just about business, but also – and above all – about the ability to implement development and work models that place People at the centre of our philosophy and our activities', said Licenziati. Indeed, it was on August 19, 1985, that Licenziati took over the management of the Ticino-based company, founded in Lugano in 1945, redefining its vision and strategy. At that time, IBSA had just 40 employees and a turnover of 5 million Swiss francs. However, by the end of the 1980s – in just 5 years – the company had radically transformed, tripling its revenue. The history of IBSA is the story of a company that evolved from a small pharmaceutical laboratory in the Swiss Canton Ticino into a multinational corporation. What many people saw as an impossible mission, President Licenziati embraced as a challenge to be won, with the aim of forging a new path, focused on innovation and the ability to respond to people's actual needs. 'Small companies can only grow if they can adapt quickly to sectors that large pharmaceutical companies often overlook', added Licenziati. 'Over the years, we have transformed an idea –producing 'drugs in the best form' – into a concrete and successful project, focusing on targeted research that meets the everyday needs of doctors and patients. We have always been a forward-looking company, ready to go beyond and willing to explore new, uncharted paths'. Since the 1990s, IBSA has embarked on a global expansion, first in Europe and then worldwide. Today the company has 20 subsidiaries across Europe, China and the United States, and distributes its products in over 90 countries across 5 continents, with more than 2,300 employees between headquarters, subsidiaries and production sites. For further information: Helen Pope PR [email protected] About IBSA IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical company with 20 subsidiaries in Europe, China and the United States. Its products are distributed in over 90 countries and its research and development activity focuses on 10 therapeutic areas. In 2025, IBSA celebrates the 40th anniversary of its acquisition by current President and CEO Arturo Licenziati, who transformed the company into a multinational that employs over 2,300 people worldwide. IBSA's growth and development can be attributed to the ability to innovate by perfecting already known molecules, as well as to the desire to look to the future in a responsible and transparent way, thanks to the dedication and dynamism of its people. IBSA Pharma® Ltd became an affiliate of IBSA Institut Biochimique SA (IBSA), following the acquisition of its UK distributor Pharmasure® in May 2022. For over 20 years, Pharmasure distributed IBSA products in the UK becoming a major contributor to the UK reproductive medicine field. The combination of Pharmasures UK knowledge and dedicated people, along with the direct support from the IBSA group will ensure we can keep delivering excellence in fertility to best support the patients. Aligned with our parent company, IBSA Pharma® Ltd became an affiliate of IBSA Institut Biochimique SA (IBSA), following the acquisition of its UK distributor Pharmasure® in May 2022. For over 20 years, Pharmasure distributed IBSA products in the UK becoming a major contributor to the UK reproductive medicine field. The combination of Pharmasures UK knowledge and dedicated people, along with the direct support from the IBSA group will ensure we can keep delivering excellence in fertility to best support the patients. Aligned with our parent company, IBSA Pharma UK has a patient-centered approach. We work closely with our customers, listening and understanding the challenges. This way we can best respond and support the needs and requirements, to enhance the service and patient experience beyond the treatment. At IBSA Pharma, we believe that our people are our most valuable assets. We are proud of our dedicated and passionate team. We work hard to develop our team and to keep improving our capabilities. has a patient-centered approach. We work closely with our customers, listening and understanding the challenges. This way we can best respond and support the needs and requirements, to enhance the service and patient experience beyond the treatment. At IBSA Pharma, we believe that our people are our most valuable assets. We are proud of our dedicated and passionate team. We work hard to develop our team and to keep improving our capabilities. Mrs Helen Pope Helen Pope PR Ltd +44 7879 818247 Visit us on social media: Legal Disclaimer:
